# US 2004/0063156 A1 · Materials and methods relating to the diagnosis and treatment of diabetes and obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0063156 A1
- Document ID: US20040063156A1
- Status: Published application
- Kind: A1
- Application number: 10/666,511
- Filed: 2003-09-17
- Published: 2004-04-01
- Earliest claimed: 1996-09-11
- Assignees: Rodaris Pharmaceuticals Limited
- Inventors: Thomas William Rademacher; Patricia McLean
- Web page: https://patentgrep.com/patent/US20040063156A1

## CPC

- G01N 33/66: involving blood sugars, e.g. galactose
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 16/18: against material from animals or humans
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The diagnosis of diabetes based on the level or ratio of P- and A-type inositolphosphoglycans (IPGs) in a sample from a patient, and the use of P- and A-type IPGs or their antagonists in the treatment of diabetes is disclosed. In particular, the present invention provides treatment of IDDM or lean type II diabetes (NIDDM) with a mixture of P- and A-type mediators, and treatment of obese type II diabetes (NIDDM) with a P-type mediator and/or an A-type antagonist.

## Claims

### Claim 1

A method of diagnosing diabetes, the method comprising determining the level or ratio of P- and/or A-type inositolphosphoglycans (IPGs) in a biological sample from a patient.

### Claim 2 (depends on 1)

The method of claim 1 wherein the biological sample is a blood or urine sample.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2 wherein the level of the P- or A-type IPGs is determined using an assay for one of their biological activities.

### Claim 4 (depends on 3)

The method of claim 3 wherein the level of the P-type IPGs is determined in an assay measuring activation of pyruvate dehydrogenase phosphatase by P-type IPGs.

### Claim 5 (depends on 3)

The method of claim 3 wherein the level of the A-type IPGs is determined in an assay measuring activation of lipogenesis by A-type IPGs in isolated adipocytes.

### Claim 6 (depends on 1, 3)

The method of claim 1 or claim 3, wherein the level of the P- or A-type IPGs is determined using a binding agent capable of specifically binding P- or A-type IPGs.

### Claim 7 (depends on 6)

The method of claim 6 wherein the binding agent is an anti-IPG antibody or an IPG specific binding protein.

### Claim 8 (depends on 1, 2)

The method of claim 1 or claim 2 wherein the method comprises the steps of:
(a) contacting a biological sample obtained from the patient with a solid support having immobilised thereon a first binding agent having binding sites specific for one or more P-type IPGs and a second binding agent having binding sites for one or more A-type IPGs;
(b) contacting the solid support with one or more labelled developing agents capable of binding to unoccupied binding sites, bound IPGs or occupied binding sites; and,
(c) detecting the label of the developing agents specifically binding in step (b) to obtain values representative of the levels of the P- and A-type IPGs in the sample.

### Claim 9 (depends on 8)

The method of claim 8 comprising the further step of:
(d) using the values to obtain a ratio of the P- and A-type IPGs in the sample.

### Claim 10

Use of P- or A-type inositolphosphoglycans (IPGs), or antagonists to P- or A-type IPGs, in the preparation of a medicament for the treatment of diabetes.

### Claim 11 (depends on 10)

The use of claim 10 wherein the medicament is formulated to provide a ratio of P- and A-type IPGs in a patient having diabetes of from about 4:1 to about 6:1.

### Claim 12 (depends on 11)

The use of claim 11 wherein the ratio of P- and A-type IPGs is about 6:1 for a male patient and about 4:1 for a female patient.

### Claim 13

Use of a P-type IPG arid/or an A-type IPG antagonist in the preparation of a medicament for the treatment of obese type II diabetes.

### Claim 14

Use of a mixture of P-type and A-type IPGs in the preparation of a medicament for the treatment of IDDM or lean type II diabetes (NIDDM).

### Claim 15 (depends on 14)

The use of claim 14 wherein the P- and A-type IPGs are in the ratio of about 6:1 for male patients and about 4:1 mixture for female patients.

### Claim 16

A pharmaceutical composition comprising a P-type IPG and/or an A-type IPG antagonist in combination with a pharmaceutically acceptable carrier.

### Claim 17

A pharmaceutical composition comprising a mixture of P- and A-type IPGs in combination with a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17 wherein the P/A-type IPG ratio is from about 4:1 to about 6:1.

### Claim 19

A method of screening for P- or A-type IPG antagonists, the method comprising:
(a) contacting a candidate antagonist and a P- or A-type IPG in an assay for a biological property of the P- or A-type IPG under conditions in which the IPG and the candidate antagonist can compete;
(b) measuring the biological property of the IPG; and,
(c) selecting candidate antagonists which reduce the biological activity of the IPG.
